Radiologists' role in breast cancer staging: Providing key information for clinicians

Radiographics

Volumn 34, Issue 2, 2014, Pages 330-342

  Lee, Sandy C ^a   Jain, Payal A ^a   Jethwa, Samir C ^a   Tripathy, Debu ^b   Amashita, Mary W Y ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST NEOPLASMS; CANCER STAGING; DIAGNOSTIC IMAGING; FEMALE; HUMAN; PHYSICIAN ATTITUDE; RADIOLOGY;

BREAST NEOPLASMS; DIAGNOSTIC IMAGING; FEMALE; HUMANS; NEOPLASM STAGING; PHYSICIAN'S ROLE; RADIOLOGY;

EID: 84896847495     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.342135071     Document Type: Article

References (46)

1. What are the key statistics about breast cancer? American Cancer Society. http://www.cancer.org /cancer/breastcancer/detailedguide/breast-cancer-key-statistics. Last revised December 31, 2013. Accessed March 20, 2013.
2. American Joint Committee on Cancer. Breast. In: Edge SB, Byrd DR, Compton CC, et al, eds. AJCC cancer staging manual. 7th ed. New York, NY: Springer, 2010; 347-376.
3. Breast cancer survival rates by stage. American Cancer Society. National Cancer Data Base. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage. Last revised December 31, 2013. Accessed March 20, 2013.
4. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005; 200(4):516-526.
5. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Bal-lard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 2000;160(7):953-958.
6. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Co-operative Group and EORTC Radiotherapy Group. Lancet 1999;355(9203):528-533.
7. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353(9169): 1993-2000.
8. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001;25(6):767-772.
9. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma: is it indicated? Cancer 1994;73(3):664-667.
10. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996;14(3): 754-763.
11. Zelis JJ, Sickle-Santanello BJ, Liang WC, Nims TA. Do not contemplate invasive surgery for ductal carcinoma in situ. Am J Surg 2002;184(4):348-349.
12. Morris EA, Schwartz LH, Drotman MB, et al. Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000;214(1):67-72.
13. Kazama T, Nakamura S, Doi O, Suzuki K, Hirose M, Ito H. Prospective evaluation of pectoralis muscle invasion of breast cancer by MR imaging. Breast Cancer 2005;12(4):312-316.
14. Cristofanilli M, Buzdar AU, Hortobágyi GN. Update on the management of infammatory breast cancer. Oncologist 2003;8(2):141-148.
15. Günhan-Bilgen I, Ustün EE, Memiş A. Infammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology 2002;223(3):829-838.
16. Lynch SP, Lei X, Chavez-MacGregor M, et al. Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 2012;23(12): 3063-3069.
17. Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA. Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 2009;117(2): 365-370.
18. Egan RL. Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer 1982;49(6):1123-1130.
19. Wilkinson LS, Given-Wilson R, Hall T, Potts H, Sharma AK, Smith E. Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound. Clin Radiol 2005;60 (5):573-578.
20. Sardanelli F, Giuseppetti GM, Panizza P, et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roent-genol 2004;183(4):1149-1157.
21. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26(19):3248-3258.
22. Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011;378(9805):1804-1811.
23. Whitman GJ, Sheppard DG, Phelps MJ, Gonzales BN. Breast cancer staging. Semin Roentgenol 2006; 41(2):91-104.
24. Newman LA, Sahin AA, Cunningham JE, et al. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer 2001;91(10): 1845-1853.
25. Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 2009;27(33):5640-5649.
26. Boetes C, Mus RD, Holland R, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 1995;197(3):743-747.
27. Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003;98(3):468-473.
28. Lee SG, Orel SG, Woo IJ, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003;226(3):773-778.
29. Plana MN, Carreira C, Muriel A, et al. Magnetic resonance imaging in the preoperative assessment of patients with primary breast cancer: systematic review of diagnostic accuracy and meta-analysis. Eur Radiol 2012;22(1):26-38.
30. Yamashita M, Hovanessian-Larsen L, Sener SF. The role of axillary ultrasound in the detection of metas-tases from primary breast cancers. Am J Surg 2013; 205(3):242-244, discussion 244-245.
31. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349(6):546-553.
32. Mansel RE, Fallowfeld L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98(9):599-609.
33. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8(10):881-888.
34. Gill G; SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009;16(2):266-275.
35. Giuliano AE, McCall L, Beitsch P, et al. Locore-gional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252(3):426-432, discussion 432-433.
36. Yang WT. Staging of breast cancer with ultrasound. Semin Ultrasound CT MR 2011;32(4):331-341.
37. Ahn JH, Son EJ, Kim JA, et al. The role of ultraso-nography and FDG-PET in axillary lymph node staging of breast cancer. Acta Radiol 2010;51(8): 859-865.
38. Yang WT, Ahuja A, Tang A, Suen M, King W, Metreweli C. Ultrasonographic demonstration of normal axillary lymph nodes: a learning curve. J Ultrasound Med 1995;14(11):823-827.
39. Bedi DG, Krishnamurthy R, Krishnamurthy S, et al. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. AJR Am J Roentgenol 2008;191(3):646-652.
40. Alvarez S, Añorbe E, Alcorta P, López F, Alonso I, Cortés J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 2006;186(5): 1342-1348.
41. Yang WT, Ahuja A, Tang A, Suen M, King W, Me-treweli C. High resolution sonographic detection of axillary lymph node metastases in breast cancer. J Ultrasound Med 1996;15(3):241-246.
42. Yang WT, Chang J, Metreweli C. Patients with breast cancer: differences in color Doppler fow and grayscale US features of benign and malignant axillary lymph nodes. Radiology 2000;215(2):568-573.
43. Damera A, Evans AJ, Cornford EJ, et al. Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. Br J Cancer 2003;89(7):1310-1313.
44. Ravaioli A, Pasini G, Polselli A, et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 2002;72(1):53-60.
45. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 1988;81(9):1109-1112.
46. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Breast Cancer. Version 2.2013. http://www.nccn.org/. Published March 11, 2013. Accessed March 30, 2013.